Stock Gumshoe
Become a member

JohnM

Author Archives

Recent Author Comments

On Biotech Discussion... continued
Posted on August 7, 2018
$BLPH long (ouch), rumrunner, thanks for your thoughts. When you say "INO pulse could not sustain patients beyond very short term" what do you mean? I thought the Phase 3 primary endpoint of 6-minute walk improvement was the same as the successful Phase 2[...]
On Biotech Discussion... continued
Posted on July 21, 2018
I doubt the expense money raised even covered his out-of-pocket expenses, but I really don’t know. I certainly agree with you on $ARTH, which is my biggest position.[...]
On Biotech Discussion... continued
Posted on July 21, 2018
Thin-skinned with anger issues, yes. Don't know what "man-child" means. Con artist? No way. I've been investing in biotech since Genentech came public and have years of exposure to Wall Street and private research. KSS is the best analyst of early-stage sc[...]
On Biotech Discussion... continued
Posted on July 9, 2018
$BNTC np and will never have one, ipaglee, a simple Google search will often answer your questions https://www.google.com/search?q=benitec&source=lnt&tbs=qdr:d&sa=X&ved=0ahUKEwik7bjp-5LcAhWHFHwKHRZ8B4QQpwUIIQ&biw=1396&bih=678[...]
On Biotech Discussion... continued
Posted on July 6, 2018
$CLRB np Voting on a reverse split between 1-for-5 and 1-for-10[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Posted on June 29, 2018
I worry a lot more about biotech companies that can’t raise money than those that can. This $4.5 million will carry ARTH into the December 2019 quarter, so we will get the results of the sensitization study, the 510(k) filing, the CE Mark filing, the 510[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Posted on June 29, 2018
Do you mean the October 2018 submission? Norchi only burns $1.3 million a quarter and said before the raise that he had enough money to get into the December quarter. He now has enough to get through the September 2019 quarter. Why on earth would he have t[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Posted on June 29, 2018
$ARTH long What do you mean by “if they don’t have to go back to the well before October”?[...]
On Biotech Discussion... continued
Posted on June 26, 2018
$AKAO np, good SeekingAlpha explanation https://seekingalpha.com/instablog/498952-bret-jensen/5179287-play-now-achaogen[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Posted on June 21, 2018
$DMCAF, wow, Cleveland, great stuff! There goes my weekend...DD time.[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Posted on June 19, 2018
STM, I'm always interested in your posts and completely agree that Norchi is extra careful about inside information. From his years running a biotech fund, he's also very knowledgeable about the issue. The sensitization study takes three months, not a f[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Posted on June 19, 2018
Glad to, billy. Norchi lined up all the people needed for the sensitivity test, got them enrolled, and started the test last week. The FDA must have asked for a three-month test. Of course, it is open-label, so ARTH can accumulate data as they go. At the e[...]
On Friday File: An "Independence Day Royalties" Guess, plus Real Money Portfolio updates
Posted on June 19, 2018
Use the search function above and you'll get your answer.[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Posted on June 17, 2018
$ARTH long. In addition to the two-week turnaround to get the 510(k) filed by the end of September, Norchi committed to file the CE Mark application around the same time - he said it is a "second half event." Also, he said "around the end of the year, [...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Posted on June 7, 2018
Even worse, NASDAQ double-counts each trade. You sell 100 shares to a market maker and they sell those 100 shares to me. NASDAQ reports 200 shares traded, even though only 100 shares moved from one holder to another. So really only $100,000 of ARTH traded [...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Posted on June 7, 2018
Norchi said he will start the sensitivity study in the next three weeks, but he didn't say he had started it already, so those who were expecting the "already" announcement sold. I guess they think they are clever enough to buy it back before he makes the [...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Posted on June 6, 2018
Correct. He will have to raise cash soon. I expect him to go to his current investors to either reprice old warrants so they exercise them now or maybe do a convertible bond. But he could have to do a stock sale. That would come after they PR that the sens[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Posted on June 5, 2018
You are right. As soon as Norchi realized the CE Mark would be delayed, he split the planned FDA filing into two parts, a 510(k) for external use that could be approved relatively quickly, and an IND for internal use that will require another clinical tria[...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Posted on June 5, 2018
No, the CE Mark is a safety approval that is much easier to get - you don't even have to do a clinical trial. (But you have to get approval from each individual country for reimbursement, and good luck getting that without strong clinical results.) An FDA [...]
On Microblog: Discussion page for Arch Therapeutics (ARTH)
Posted on June 5, 2018
The trial is 90 days long. I am talking about the length of time the FDA will review the refiled 510(k) application before giving ARTH final approval.[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

Connect with Travis

website designed by Gravity Switch